Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 3/20 | 0.53 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.53 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | ALPL | P05186 | 2/20 | 0.48 |
| ▸ | RIPK1 | Q13546 | 9/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | SCD | O00767 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19224520 | 0.87 | NR1H2 (0.56) | NR1H2NR1H3KLKB1NPC1POLB | |
| SCHEMBL24193687 | 0.84 | ALPL (0.48) | KLKB1ALPLRIPK1HDAC6 | |
| SCHEMBL23085471 | 0.84 | NR1H2 (0.53) | NR1H2NR1H3KLKB1NPC1POLB | |
| SCHEMBL28824358 | 0.83 | RNASEH1 (0.56) | NR1H2NR1H3KLKB1NPC1POLB | |
| SCHEMBL30848602 | 0.83 | NR1H2 (0.51) | NR1H2NR1H3KLKB1NPC1POLB | |
| SCHEMBL3104472 | 0.82 | SMN1; SMN2 (0.53) | NR1H2NR1H3KLKB1NPC1POLB | |
| SCHEMBL25586405 | 0.80 | KLKB1 (0.55) | NR1H2NR1H3KLKB1RIPK1HDAC6 | |
| SCHEMBL28042800 | 0.80 | NR1H2 (0.49) | NR1H2NR1H3KLKB1NPC1POLB | |
| SCHEMBL31272348 | 0.77 | ADORA3 (0.58) | NR1H2NR1H3KLKB1NPC1POLB | |
| SCHEMBL553327 | 0.77 | TSHR (0.50) | NR1H2NR1H3KLKB1NPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265100-A1 | RIP1K INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-11718612-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-08-08 | — | — | US | disclosed |
| US-11667643-B2 | RIP1K inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20220009936-A1 | RIP1K INHIBITORS | MIDCAP FINANCIAL TRUST | 2022-01-13 | — | — | US | disclosed |
| WO-2022005898-A1 | RIP1K INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2022-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718612-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | RIPK1, RIPK2, RIPK4 | NR1H2 1198/4885NR1H3 1397/4885KLKB1 3311/4885 |
| US-20230265100-A1 | RIP1K INHIBITORS | RIPK1, RIPK2, RIPK3 | NR1H2 1673/4885NR1H3 1797/4885KLKB1 2471/4885 |
| US-20220009936-A1 | RIP1K INHIBITORS | RIPK1, RIPK2, RIPK3 | NR1H2 1673/4885NR1H3 1797/4885KLKB1 2471/4885 |
| US-11667643-B2 | RIP1K inhibitors | RIPK1, RIPK2, RIPK3 | NR1H2 1673/4885NR1H3 1797/4885KLKB1 2471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.